Go Pro
→ They're not buying gold. They're buying this. (From Behind the Markets) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
$41.03
$34.89
$16.10
▼
$41.14
$5.25B-0.247.54 million shs68.61 million shs
Biogen Inc. stock logo
BIIB
Biogen
$225.36
+2.9%		$211.87
$135.39
▼
$226.43
$32.37B0.17788,847 shs1.11 million shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
0.00%0.00%0.00%0.00%+78.31%
Biogen Inc. stock logo
BIIB
Biogen
+1.66%+0.79%+1.06%+11.10%+53.73%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
$41.03
$34.89
$16.10
▼
$41.14
$5.25B-0.247.54 million shs68.61 million shs
Biogen Inc. stock logo
BIIB
Biogen
$225.36
+2.9%		$211.87
$135.39
▼
$226.43
$32.37B0.17788,847 shs1.11 million shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
0.00%0.00%0.00%0.00%+78.31%
Biogen Inc. stock logo
BIIB
Biogen
+1.66%+0.79%+1.06%+11.10%+53.73%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
2.14
Hold$38.88-5.25% Downside
Biogen Inc. stock logo
BIIB
Biogen
2.58
Moderate Buy$230.142.12% Upside

Current Analyst Ratings Breakdown

Latest BIIB and APLS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/10/2026
Biogen Inc. stock logo
BIIB
Biogen
Stifel Nicolaus logo
Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$242.00
9/10/2026
Biogen Inc. stock logo
BIIB
Biogen
HSBC Holdings plc logo
HSBC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetReduce$165.00 ➝ $175.00
9/3/2026
Biogen Inc. stock logo
BIIB
Biogen
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$225.00 ➝ $245.00
8/25/2026
Biogen Inc. stock logo
BIIB
Biogen
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$240.00 ➝ $260.00
8/13/2026
Biogen Inc. stock logo
BIIB
Biogen
Wolfe Research logo
Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradePeer Perform ➝ Outperform$300.00
8/12/2026
Biogen Inc. stock logo
BIIB
Biogen
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold (C) ➝ Hold (C-)
8/4/2026
Biogen Inc. stock logo
BIIB
Biogen
Mizuho logo
Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$221.00 ➝ $241.00
8/3/2026
Biogen Inc. stock logo
BIIB
Biogen
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$200.00 ➝ $215.00
7/30/2026
Biogen Inc. stock logo
BIIB
Biogen
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$237.00 ➝ $251.00
7/30/2026
Biogen Inc. stock logo
BIIB
Biogen
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$242.00 ➝ $240.00
7/28/2026
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
Needham & Company LLC logo
Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$83.00
(Data available from 9/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
$1.11B4.75$0.21 per share196.33$3.24 per share12.66
Biogen Inc. stock logo
BIIB
Biogen
$9.89B3.37$23.28 per share9.68$124.45 per share1.81
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
$22.39M$1.0240.23N/AN/A12.06%39.71%13.20%N/A
Biogen Inc. stock logo
BIIB
Biogen
$1.29B$5.6539.8913.992.428.32%11.18%6.88%10/28/2026 (Estimated)

Latest BIIB and APLS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/29/2026Q2 2026
Biogen Inc. stock logo
BIIB
Biogen
$2.94$3.60+$0.66$0.66$2.46 billion$2.74 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
N/AN/AN/AN/AN/A
Biogen Inc. stock logo
BIIB
Biogen
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
0.87
3.63
3.16
Biogen Inc. stock logo
BIIB
Biogen
0.39
1.87
1.26

Institutional Ownership

CompanyInstitutional Ownership
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
96.29%
Biogen Inc. stock logo
BIIB
Biogen
87.93%

Insider Ownership

CompanyInsider Ownership
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
6.50%
Biogen Inc. stock logo
BIIB
Biogen
0.25%
CompanyEmployeesShares OutstandingFree FloatOptionable
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
770128.02 million119.70 millionOptionable
Biogen Inc. stock logo
BIIB
Biogen
7,500147.75 million147.39 millionOptionable

Recent News About These Companies

Why Biogen (BIIB) Stock Just Broke to a Fresh 52-Week High
September 22 at 2:52 PM  |  coincentral.comC
Biogen (BIIB) Stock Surges to 52-Week Peak Amid Stellar Earnings Performance
September 22 at 2:52 PM  |  moneycheck.comM
Biogen (NASDAQ:BIIB) Sets New 52-Week High - What's Next?
September 22 at 12:39 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-biogen-nasdaq-biib-sets-new-52-week-high-whats-next-2026-09-22/
Biogen (BIIB) Stock Surges to New 52-Week Peak on Earnings Beat and Analyst Optimism
September 22 at 11:51 AM  |  blockonomi.comhttps://blockonomi.com/biogen-biib-stock-surges-to-new-52-week-peak-on-earnings-beat-and-analyst-optimism/
Biogen stock heads into the open after a 1.6 percent decline
September 22 at 9:52 AM  |  ad-hoc-news.deA
Nykredit A S Makes New $8.02 Million Investment in Biogen Inc. $BIIB
September 22 at 3:21 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-nykredit-a-s-makes-new-802-million-investment-in-biogen-inc-biib-2026-09-22/
Novo Nordisk shares plunge over 7% as new targets fail to reassure investors
September 21 at 1:47 PM  |  proactiveinvestors.comhttps://www.proactiveinvestors.com/companies/news/1098834/novo-nordisk-shares-plunge-over-7-as-new-targets-fail-to-reassure-investors-1098834.html
4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day
September 21 at 1:47 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/4-alzheimers-drug-stocks-watch-164000961.html
4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day
September 21 at 1:40 PM  |  zacks.comhttps://www.zacks.com/stock/news/2993189/4-alzheimer-s-drug-stocks-to-watch-on-world-alzheimer-s-day?cid=cs-stocknewsapi-ft-analyst_blog|investment_ideas-2993189
Biogen stock heads into the open after a 1.6 percent slide
September 21 at 3:44 AM  |  ad-hoc-news.deA
Biogen Inc. stock reacts to Leqembi Pen approval and fresh guidance
September 20 at 10:09 PM  |  ad-hoc-news.deA
Biogen Publishes EMPAVELI Data Showing Reduced Proteinuria In Adolescents With Kidney Diseases
September 18, 2026  |  rttnews.comhttps://www.rttnews.com/3692126/biogen-publishes-empaveli-data-showing-reduced-proteinuria-in-adolescents-with-kidney-diseases.aspx
Biogen Inc.: Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in ...
September 18, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-09/69611469-biogen-inc-phase-3-pediatric-empaveli-data-published-in-clinical-journal-of-the-american-society-of-nephrology-show-reduction-in-proteinuria-and-sta-399.htm
Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN
September 17, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/phase-3-pediatric-empaveli-data-201500924.html
Biogen Announces Published VALIANT Data Showing EMPAVELI Reduced Proteinuria in Adolescents with C3G and Primary IC-MPGN
September 17, 2026  |  quiverquant.comQ
Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN
September 17, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/17/3364391/0/en/phase-3-pediatric-empaveli-data-published-in-clinical-journal-of-the-american-society-of-nephrology-show-reduction-in-proteinuria-and-stabilized-kidney-function-in-adolescents-with.html
Biogen: Growth Is Back, But It Came At A Price
September 17, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4947430-biogen-growth-is-back-but-it-came-at-a-price?utm_source=marketbeat.com&utm_medium=referral&feed_item_type=article?source=MarketBeat
Corient Private Wealth LP Raises Stock Holdings in Biogen Inc. $BIIB
September 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-corient-private-wealth-lp-raises-stock-holdings-in-biogen-inc-biib-2026-09-17/
Bank of America Corp DE Invests $241.17 Million in Biogen Inc. $BIIB
September 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-invests-24117-million-in-biogen-inc-biib-2026-09-17/
Baird Financial Group Inc. Increases Stock Holdings in Biogen Inc. $BIIB
September 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-baird-financial-group-inc-increases-stock-holdings-in-biogen-inc-biib-2026-09-17/
Is Biogen Stock Outperforming the S&P 500?
September 16, 2026  |  barchart.comhttps://www.barchart.com/story/news/4629929/is-biogen-stock-outperforming-the-s-p-500

New MarketBeat Followers Over Time

Media Sentiment Over Time

Apellis Pharmaceuticals stock logo

Apellis Pharmaceuticals NASDAQ:APLS

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Biogen stock logo

Biogen NASDAQ:BIIB

$225.36 +6.29 (+2.87%)
Closing price 04:00 PM Eastern
Extended Trading
$223.94 -1.42 (-0.63%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas